Threshold Plummets As Merck Drops Evofosfamide For Sarcoma

Threshold Pharmaceuticals saw its stock lose more than 80% of its value following disappointing data from two Phase III trials of its anticancer evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. Its partner, Germany's Merck, said it would not be filing for approval of the product.